AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11778791 — intervention group
Group type: EXPERIMENTAL
Intervention: Taifun (50 microg dose(-1) metered-dose dry powder inhaler)
Number of subjects: 21
Study 11778791 — intervention group
Group type: COMPARATOR
Intervention: Turbuhaler (50 microg dose(-1) dry powder inhaler)
Number of subjects: 21
Study 11778791 — intervention group
Group type: COMPARATOR
Intervention: pMDI+S (100 microg dose(-1) pressurized metered-dose inhaler with a spacer)
Number of subjects: 21
Study 8998204 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-first method (telephone interviews with follow-up of nonrespondents by mail)
Number of subjects: 252
Study 8998204 — intervention group
Group type: COMPARATOR
Intervention: Mail-first method (mailed surveys with follow-up on nonrespondents by telephone)
Number of subjects: 252
Study 8998204 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-first method
Number of subjects: 252
Study 8278215 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 47
Study 8278215 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine
Number of subjects: 47
Study 3318428 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone 1,000 mg taken at bedtime
Number of subjects: 264
Study 3318428 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 900 mg four times daily
Number of subjects: 264
Study 29384571 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional Education (IPE) activity with nonhealth care students
Number of subjects: 0
Study 29384571 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 26662031 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra‐rapid opioid detoxification (UROD) combined with naltrexone treatment (NMT)
Number of subjects: 14
Study 26662031 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 14
Study 25311370 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based self-management program with telephone coaching (8-week program)
Number of subjects: 29
Study 25311370 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no access to the website, weekly telephone call as attention-strategy)
Number of subjects: 29
Study 23900058 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplementation of a bacterial lysate between week 5 and the end of month 7 (intervention group)
Number of subjects: 571
Study 23900058 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 571
Study 19761514 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (15 min daily, 5 days/week for 4 weeks)
Number of subjects: 24
Study 19761514 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (light still touch, same duration as intervention)
Number of subjects: 24
Study 19761514 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 24
Study 18851788 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CRT) with cisplatin plus 5-fluorouracil
Number of subjects: 44
Study 18851788 — intervention group
Group type: COMPARATOR
Intervention: Late course accelerated hyperfractionated radiotherapy (LCAF)
Number of subjects: 44
Study 16627810 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin treatment
Number of subjects: 2359
Study 16627810 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 2359
Study 16627810 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined assessment of troponin-T and sCD40L
Number of subjects: 2359
Study 14616460 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching the cystoscopy on closed‐circuit television with an explanation during the procedure
Number of subjects: 51
Study 14616460 — intervention group
Group type: COMPARATOR
Intervention: Explanations alone
Number of subjects: 51
Study 10993781 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 48
Study 10993781 — intervention group
Group type: COMPARATOR
Intervention: Control (no vitamin C)
Number of subjects: 48
Study 8638548 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fluorouracil (5FU) 400 mg/m2, days 1‐5 and folinic acid (FA) 200 mg/m2, days 1‐5
Number of subjects: 55
Study 8638548 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fluorouracil (5FU) 400 mg/m2, days 1‐5 and folinic acid (FA) 200 mg/m2, days 1‐5 with ifosfamide (IFO) 5 g/m2, day 1 and Mesna
Number of subjects: 55
Study 1294028 — intervention group
Group type: EXPERIMENTAL
Intervention: Early instillation of mitomycin
Number of subjects: 0
Study 1294028 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall early instillation therapy
Number of subjects: 0
Study 1294028 — intervention group
Group type: COMPARATOR
Intervention: Late instillation of mitomycin
Number of subjects: 0
Study 1294028 — intervention group
Group type: COMPARATOR
Intervention: Early instillation of adriamycin
Number of subjects: 0
Study 1294028 — intervention group
Group type: COMPARATOR
Intervention: Late instillation of adriamycin
Number of subjects: 0
Study 6492907 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate Sickness Impact Profile (SIP) score
Number of subjects: 66
Study 6492907 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate SIP
Number of subjects: 66
Study 6492907 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate SIP total and dimension scores
Number of subjects: 66
Study 30620771 — intervention group
Group type: COMPARATOR
Intervention: Hypothetical community-based health insurance (CBHI) schemes with various benefit package components including insurance coverage for medical consultations, hospitalizations, traffic accidents, pharmaceuticals, transportation, premiums, and prepaid discounts.
Number of subjects: 5800
Study 29401325 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV-preF vaccine (30 µg nonadjuvanted)
Number of subjects: 0
Study 29401325 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV-preF vaccine (60 µg nonadjuvanted)
Number of subjects: 0
Study 29401325 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV-preF vaccine (60 µg aluminum-adjuvanted)
Number of subjects: 0
Study 29401325 — intervention group
Group type: COMPARATOR
Intervention: Tdap vaccine (control)
Number of subjects: 0
Study 26920602 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued novel oral anticoagulant (dabigatran, rivaroxaban, or apixaban)
Number of subjects: 0
Study 26920602 — intervention group
Group type: COMPARATOR
Intervention: Interrupted novel oral anticoagulant (dabigatran, rivaroxaban, or apixaban)
Number of subjects: 0
Study 26920602 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued novel oral anticoagulant
Number of subjects: 0
Study 26920602 — intervention group
Group type: COMPARATOR
Intervention: Interrupted novel oral anticoagulant
Number of subjects: 0
Study 24457590 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (N=47)
Number of subjects: 149
Study 24457590 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST; 12 total sessions, N=53)
Number of subjects: 149
Study 24457590 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N=49)
Number of subjects: 149
Study 22169268 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant breast radiotherapy (n=942)
Number of subjects: 1613
Study 22169268 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostate radiotherapy (n=637)
Number of subjects: 1613
Study 20969657 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohesive polydensified matrix hyaluronic acid (CPMHA)
Number of subjects: 95
Study 17197012 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (LAVH/BSO)
Number of subjects: 1312
Study 17197012 — intervention group
Group type: COMPARATOR
Intervention: Postoperative adjuvant whole pelvic radiation therapy (WPRT)
Number of subjects: 1312
Study 17197012 — intervention group
Group type: COMPARATOR
Intervention: Intravaginal radiation therapy (IVRT)
Number of subjects: 1312
Study 17197012 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 1312
Study 17197012 — intervention group
Group type: EXPERIMENTAL
Intervention: Total direct medical costs
Number of subjects: 1312
Study 15781667 — intervention group
Group type: EXPERIMENTAL
Intervention: High selenium level (4th versus 1st quartile) among men with AA genotype
Number of subjects: 1331
Study 15781667 — intervention group
Group type: EXPERIMENTAL
Intervention: High selenium level among men with VV/VA genotype
Number of subjects: 1331
Study 15781667 — intervention group
Group type: COMPARATOR
Intervention: Beta-carotene treatment among men with AA genotype
Number of subjects: 1331
Study 15781667 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of antioxidants (selenium, lycopene, alpha-tocopherol) among men with AA genotype
Number of subjects: 1331
Study 12110034 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH)
Number of subjects: 68
Study 12110034 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rhGH)
Number of subjects: 68
Study 12110034 — intervention group
Group type: EXPERIMENTAL
Intervention: Post one year (all groups receiving rhGH)
Number of subjects: 68
Study 12110034 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68
Study 10422040 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen 0.625 mg daily plus progestogen (norgestrel) 150 micrograms for the last 12 days of each 28 day cycle
Number of subjects: 38
Study 10422040 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/day for 28 days
Number of subjects: 38
Study 10422040 — intervention group
Group type: COMPARATOR
Intervention: Both groups combined
Number of subjects: 38
Study 7758644 — intervention group
Group type: EXPERIMENTAL
Intervention: Tampon A
Number of subjects: 41
Study 2083474 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial prebrushing rinse (Plax)
Number of subjects: 16
Study 2083474 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 16
Study 343738 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol administered 1 to 2 hours prior to operation (Group 2)
Number of subjects: 27
Study 343738 — intervention group
Group type: COMPARATOR
Intervention: Propranolol discontinued 48 hours prior to operation (Group 1)
Number of subjects: 27
Study 343738 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 27
Study 29443404 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulatory formula (IF) 400 mL/d for 10 days
Number of subjects: 38
Study 29443404 — intervention group
Group type: COMPARATOR
Intervention: Commonly used formula (CF)
Number of subjects: 38
Study 26963897 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 25 mg three times daily for 12 weeks before IVF/ICSI cycles
Number of subjects: 140
Study 24793931 — intervention group
Group type: EXPERIMENTAL
Intervention: Written preoperative information (Group W)
Number of subjects: 190
Study 24793931 — intervention group
Group type: COMPARATOR
Intervention: Verbal preoperative information (Group V)
Number of subjects: 190
Study 23810122 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 40
Study 23810122 — intervention group
Group type: COMPARATOR
Intervention: Placebo rTMS
Number of subjects: 40
Study 19913254 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystoscopy with knowledge of positive urine test results (226 patients)
Number of subjects: 448
Study 19913254 — intervention group
Group type: COMPARATOR
Intervention: Cystoscopy without knowledge of positive urine test results (120 cystoscopies)
Number of subjects: 448
Study 19913254 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystoscopy with negative urine test results (260 patients in intervention arm)
Number of subjects: 448
Study 19913254 — intervention group
Group type: COMPARATOR
Intervention: Cystoscopy with negative urine test results (326 patients in control arm)
Number of subjects: 448
Study 18165149 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitatory TBS of the affected motor cortex
Number of subjects: 12
Study 18165149 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory TBS of the unaffected motor cortex
Number of subjects: 12
Study 18165149 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched healthy individuals)
Number of subjects: 12
Study 17260879 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine drugs (group 2)
Number of subjects: 30
Study 17260879 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine and GABAergic drugs (group 3)
Number of subjects: 30
Study 17260879 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group 1)
Number of subjects: 30
Study 11682404 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-dose oral buspirone (60 mg)
Number of subjects: 8
Study 11682404 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-dose IV meperidine (target plasma concentration of 0.8 microg/mL)
Number of subjects: 8
Study 11682404 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of buspirone (30 mg) and meperidine (0.4 microg/mL)
Number of subjects: 8
Study 11682404 — intervention group
Group type: COMPARATOR
Intervention: Control (no drugs)
Number of subjects: 8
Study 9728378 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional restoration program (n = 621)
Number of subjects: 816
Study 9728378 — intervention group
Group type: COMPARATOR
Intervention: Control outpatient programs (n = 144)
Number of subjects: 816
Study 9728378 — intervention group
Group type: COMPARATOR
Intervention: No treatment (n = 51)
Number of subjects: 816
Study 8069895 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT OIL (15 ml daily providing 545 kJ)
Number of subjects: 60
Study 8069895 — intervention group
Group type: COMPARATOR
Intervention: Strict reducing diet without oil
Number of subjects: 60
Study 8069895 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT OIL
Number of subjects: 60
Study 3192038 — intervention group
Group type: EXPERIMENTAL
Intervention: 40‐g low‐protein diet (LPD)
Number of subjects: 10
Study 3192038 — intervention group
Group type: COMPARATOR
Intervention: usual‐protein diet (UPD)
Number of subjects: 10
Study 1592958 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 44
Study 1592958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 354471 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone 50 mg three times daily
Number of subjects: 40
Study 354471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31904342 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary 12-week exercise-based cardiac rehabilitation program
Number of subjects: 607
Study 31556637 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomy-supportive tone of voice
Number of subjects: 1000
Study 31556637 — intervention group
Group type: COMPARATOR
Intervention: Controlling tone of voice
Number of subjects: 1000
Study 31556637 — intervention group
Group type: COMPARATOR
Intervention: Neutral tone of voice
Number of subjects: 1000
Study 27277518 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia primary crowns
Number of subjects: 56
Study 27277518 — intervention group
Group type: COMPARATOR
Intervention: Cobalt-chromium alloy primary crowns
Number of subjects: 56
Study 25912221 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 1098
Study 25912221 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 1098
Study 25912221 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 1098
Study 23692696 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with phase I Coxiella burnetii vaccine (Coxevac-Ceva Sante Animale) during advanced pregnancy
Number of subjects: 719
Study 23692696 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with phase I Coxiella burnetii vaccine
Number of subjects: 719
Study 23692696 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-vaccinated)
Number of subjects: 719
Study 21285447 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT)
Number of subjects: 62
Study 21285447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 20161310 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label rTMS (15 sessions over 3 weeks)
Number of subjects: 20
Study 17524937 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA (5 mg/kg/d) plus MMF (30 mg/kg/d) and prednisolone (1 mg/kg/d)
Number of subjects: 90
Study 17524937 — intervention group
Group type: COMPARATOR
Intervention: CsA (8 mg/kg/d) plus MMF (30 mg/kg/d) and prednisolone (1 mg/kg/d)
Number of subjects: 90
Study 14741172 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine consisting of recombinant baculovirus-derived KSA formulated with monophosphoryl lipid A (MPL) in liposomes and emulsified in mineral oil
Number of subjects: 11
Study 14741172 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine with co-administration of human recombinant GM-CSF (rGM-CSF)
Number of subjects: 11
Study 14741172 — intervention group
Group type: COMPARATOR
Intervention: Vaccine without GM-CSF
Number of subjects: 11
Study 14741172 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine
Number of subjects: 11
Study 12568014 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin/pyronaridine combination
Number of subjects: 32
Study 12568014 — intervention group
Group type: COMPARATOR
Intervention: Dihydroartemisinin
Number of subjects: 32
Study 12568014 — intervention group
Group type: COMPARATOR
Intervention: Pyronaridine
Number of subjects: 32
Study 9825744 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg weekly i.m. injections for 1 year
Number of subjects: 174
Study 9825744 — intervention group
Group type: COMPARATOR
Intervention: Gold sodium thiomalate (GSTM) 50 mg weekly i.m. injections for 1 year
Number of subjects: 174
Study 7854994 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg daily for 28 days)
Number of subjects: 31
Study 7854994 — intervention group
Group type: COMPARATOR
Intervention: Placebo (given for 14 days)
Number of subjects: 31
Study 2805601 — intervention group
Group type: COMPARATOR
Intervention: Healthy children
Number of subjects: 54
Study 2805601 — intervention group
Group type: EXPERIMENTAL
Intervention: Burned children
Number of subjects: 54
Study 809805 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose EHDP
Number of subjects: 0
Study 809805 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose EHDP
Number of subjects: 0
Study 809805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30252783 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular engagement in physical activity prior to hospitalization
Number of subjects: 242
Study 30252783 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial entry site for percutaneous coronary intervention
Number of subjects: 242
Study 30252783 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex-related and gender-related factors
Number of subjects: 242
Study 29045535 — intervention group
Group type: EXPERIMENTAL
Intervention: selumetinib 75 mg b.i.d. plus docetaxel 60 mg/m2 (SEL+DOC 60)
Number of subjects: 212
Study 29045535 — intervention group
Group type: EXPERIMENTAL
Intervention: selumetinib 75 mg b.i.d. plus docetaxel 75 mg/m2 (SEL+DOC 75)
Number of subjects: 212
Study 29045535 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus docetaxel 75 mg/m2 (PBO+DOC 75)
Number of subjects: 212
Study 26001028 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake Regional Anesthesia (RA)
Number of subjects: 722
Study 26001028 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia
Number of subjects: 722
Study 26001028 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Spinal Caudal Anesthetic
Number of subjects: 722
Study 26001028 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 722
Study 26001028 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Sedation
Number of subjects: 722
Study 26001028 — intervention group
Group type: EXPERIMENTAL
Intervention: Bloody Tap on First Attempt at Lumbar Puncture
Number of subjects: 722
Study 23590906 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (STN DBS) switched on
Number of subjects: 12
Study 23590906 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (STN DBS) switched off
Number of subjects: 12
Study 23590906 — intervention group
Group type: COMPARATOR
Intervention: Visual feedback provided during the task
Number of subjects: 12
Study 20941455 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg once daily
Number of subjects: 7337
Study 20941455 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (40 mg once‐daily or 30 mg twice‐daily)
Number of subjects: 7337
Study 18675965 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrification RT/warming RT
Number of subjects: 0
Study 18675965 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrification RT/warming 37 degrees C
Number of subjects: 0
Study 18675965 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrification 37 degrees C/warming 37 degrees C
Number of subjects: 0
Study 18675965 — intervention group
Group type: COMPARATOR
Intervention: Slow freezing RT/thawing RT
Number of subjects: 0
Study 17296165 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 16
Study 17296165 — intervention group
Group type: COMPARATOR
Intervention: Habituation Based Exposure Therapy (HBET)
Number of subjects: 16
Study 15145916 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise in adolescence
Number of subjects: 175
Study 15145916 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic exercise throughout lifetime
Number of subjects: 175
Study 15145916 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic factors
Number of subjects: 175
Study 11387182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse recall group
Number of subjects: 1906
Study 11387182 — intervention group
Group type: EXPERIMENTAL
Intervention: GP recall group
Number of subjects: 1906
Study 11387182 — intervention group
Group type: COMPARATOR
Intervention: Audit group
Number of subjects: 1906
Study 11387182 — intervention group
Group type: COMPARATOR
Intervention: Nurse recall group vs Audit group
Number of subjects: 1906
Study 11387182 — intervention group
Group type: COMPARATOR
Intervention: GP recall group vs Audit group
Number of subjects: 1906